PLI Scheme Boosts Domestic Pharma Manufacturing: 32 Projects Completed with 56,679 MT Annual Capacity

The Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates and Active Pharmaceutical Ingredients (APIs) in the Country with a financial outlay of Rs. 6,940 crores was approved by the Cabinet to boost domestic manufacturing of bulk drugs in the country, reduce import dependence and improve our supply chain resilience. The production period under the scheme is from FY 2022-23 to FY 2028-29.

Under the scheme, 249 applications were received, of which 48 projects have been selected for manufacturing of identified bulk drugs. 13 of these projects are implemented by 10 Micro, Small and Medium Enterprises (MSMEs).

Under the scheme, 32 projects have been completed with cumulative installed capacity of 56,679 MT per annum. 16 projects are under development and have been supported for facilitating regulatory approvals such as environmental clearance and drug manufacturing licenses with the help of state governments. Against the targeted investment of Rs. 3,938 crores, investments worth Rs. 4,024 crores have been made under the scheme. The details of state-wise approved projects under the scheme are attached at Annexure.

Annexure

1. Production Linked Incentive scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials (KSMs)/ Drug Intermediates and Active Pharmaceutical Ingredients (APIs) in the Country.